Is Johnson & Johnson Stock a Buy?
This healthcare blue chip is making all the right moves to reward shareholders.…
20,710€
-0,24%
Echtzeit-Aktienkurs Johnson Matthey PLC
Bid:
Ask:
Nachrichten zur Johnson Matthey PLC Aktie
Johnson & Johnsons Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
Thursday, the FDA approved Johnson & Johnson (NYSE:JNJ) Rybrevant (amivantamab-vmjw) in combination with standard-of-care chemotherapy (carboplatin and pemetrexed) for locally…
14:49: Johnson & Johnson: Aktie versucht auszubrechen
Papiere von Johnson & Johnson halten sich seit nunmehr einer Woche im Bereich eines seit April 2022 bestehenden Abwärtstrends auf…
Johnson & Johnson Aktie: Dividendenzahlung steht bevor
Die Johnson & Johnson Aktie zeigt sich in den letzten Tagen stabil und notiert aktuell bei 165,51 USD. Anleger blicken…
Johnson & Johnson: A Strategic MedTech Shift For This Dividend King
…
Chief Future Officer: Joseph Wolk, Johnson & Johnson CFO
Chief Financial Officers now play a critical role in shaping corporate strategy and positioning organizations to meet future challenges. Bloombergs…
How J&Js CFO Keeps His Footing on the Patent Cliff
Between 2024 and 2030, the largest US pharma companies will lose patent protections on drugs that now account for $180…
J&J CFO Sees Value in Tech Partnerships
Medical Technology has become a high-growth segment within the health care industry, while opening up new possibilities in patient care.…
12:28: Die meistgehandelten Produkte: Johnson & Johnson bietet Vergleich an!
Nach einer turbulenten Handelswoche zeigt der DAX® am Montag eine leichte Erholung, wobei er wieder über seine wichtigen 50- und…
Global Hematologic Malignancies Market Size To Worth USD 144.58 Billion By 2033 | CAGR Of 7.97%
The Global Hematologic Malignancies Market Size was Valued at USD 67.18 Billion in 2023 and the Worldwide Hematologic Malignancies Market…
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem @themotleyfool #stocks $JNJ $MO $INTC $WBA
Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldnt rely on their payouts.…
Johnson & Johnson wins over longtime holdout for talc settlement, WSJ reports By Reuters
Johnson & Johnson wins over longtime holdout for talc settlement, WSJ reports…
Johnson & Johnson (JNJ) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
…
Global Burn Care Market Size To Worth USD 4.88 Billion By 2033 | CAGR Of 7.3%
The Global Burn Care Market Size was Valued at USD 2.41 Billion in 2023 and the Worldwide Burn Care Market…
Is Johnson & Johnson the Best Dividend Stock for You?
…
Is Johnson & Johnson the Best Dividend Stock for You?
You wont find a more dependable dividend payer on Wall Street. But whether its the best stock for you depends…
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
The Johnson & Johnson filing seeks the FDAs approval for nipocalimab to treat generalized myasthenia gravis in a broad population…
Is Johnson & Johnson Stock a Buy?
The company hasnt performed well in recent years,…
Johnson & Johnson: The Dividend King Is Back
…
J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition
Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million. The…
Johnson & Johnson to acquire V-Wave in deal worth up to $1.1bn By Investing.com
Johnson & Johnson to acquire V-Wave in deal worth up to $1.1bn…
Johnson & Johnson gets green light for lung cancer combination treatment By Investing.com
Johnson & Johnson gets green light for lung cancer combination treatment…
Goldman belässt Astrazeneca auf Buy - Ziel 15756 Pence
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca nach veröffentlichten Fachartikeln für die anstehende…
The Markets Excessive Recession Fears
We comment on the ongoing market sell-off, in addition to featuring new research reports on Johnson & Johnson (JNJ), T-Mobile…
Invest $50K in Johnson & Johnson to Become a Dividend Millionaire in 10 Years
…
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
These two healthcare companies have far more upside potential than Johnson & Johnson.…
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now @themotleyfool #stocks $VRTX $JNJ $ISRG
These two healthcare companies have far more upside potential than Johnson & Johnson.…
Führungswechsel bei Johnson & Johnson: Urs Vögeli ist neuer Managing Director
Janssen-Cilag GmbH: Neuss (ots) - Urs Vögeli ist seit dem 1. August 2024 Vorsitzender der Geschäftsführung der Janssen-Cilag GmbH, dem…
United States Pain Management Therapeutics Market Research 2024-2032 Featuring Eli Lilly and Co, Pfizer,. GSK,c Novartis, Merck & Co, Abbott Laboratories, Johnson & Johnson, & Baxter
Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "United States Pain Management Therapeutics Market and Forecast Therapeutics (Devices…
If You Invested $1000 In Johnson & Johnson Stock 20 Years Ago, How Much Would You Have Now?
…
Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06%
The Global Regenerative Medicine Market Size was Valued at USD 31.90 Billion in 2023 and the Worldwide Regenerative Medicine Market…
Could Johnson & Johnsons Troubles With Talc Lawsuits Finally Be Coming to an End?
Is it safe to buy Johnson & Johnson stock now?…
Johnson & Johnson: Downgrade
Tokio (www.aktiencheck.de) - Rating-Update:
Narumi Nakagiri, Analystin von Daiwa Capital Markets, stuft die Aktie von Johnson & Johnson (J&J) (ISIN: US4781601046,…